Skip Navigation


The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Bookmark | Print | E-Mail

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic e-mail notifications as soon as a clinical trial is posted in the medical category you're interested in.






Home » Drug Information » FDA-Approved Drugs » 1997
Medical Areas: Cardiology/Vascular Diseases | Endocrinology

View By: Year Company Therapeutic Areas Drug Names 

Drug Information

The following information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Drug Name: REPRONEX(menotropins for injection, USP)

Company: Ferring Pharmaceuticals
Approval Status: Approved February 1997
Treatment Area: Treatment for infertility

General Information

REPRONEX, the generic equivalent of Pergonal, has been approved for the treatment of infertility. REPRONEX is a human menopausal gonadotropin (hMG), administered by intramuscular injection. Ferring has received FDA clearance to market REPRONEX for sequential use with human chorionic gonadotripin (hCG) in induction of ovulation and pregnancy in anovulatory infertile patients, and for stimulating the development of multiple follicles in ovulatory patients participating in an in vitro fertilization (IVF) program.

REPRONEX is also indicated for concomitant use with hCG for the stimulation of spermatogenesis in men who have primary or secondary hypogonadotropic hypogonadism.


Jobson Medical Information

Copyright © 1995-2009 Jobson Medical Information LLC.


Designed by Piehead Productions LLC.